Combinations of TCEs targeting CEA and/or FAP on malignant CRC tumours with immune checkpoint inhibitors, such as αCTLA4 (48, 49), may be crucial to maintain the acute efficacy of TCEs in aggressive models of peritoneal carcinomatosis and CRC metastases to lungs. Here, CEACAM5 is linked to colorectal carcinoma.